Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06153693 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
A Phase 3 study of Hypertension, sponsored by Mineralys Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,083
- Enrollment target
- 20
- Study locations
NCT06153693 is a Phase 3 study of Hypertension that has completed, run by Mineralys Therapeutics. The registered enrollment target is 1,083 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT06153693, a Phase 3 study of Hypertension, has completed, sponsored by Mineralys Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,083 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG lorundrostat Dose 1
- DRUG lorundrostat Dose 2
Study Locations (20)
California
- Entertainment Medical Group, Inc. - Beverly Hills
- Amicis Research Center - Granada Hills - Granada Hills
- Amicis Research Center - Northridge - Granada Hills
- Marvel Clinical Research, LLC - Huntington Beach
- Amicis Research Center - Northridge
- Pasadena Clinical Trials - Pasadena
- Empire Clinical Research (ECR) - Pomona
- Clinical Trials Research (CTR) - Sacramento - Sacramento
- North America Research Institute - San Dimas
- Amicis Research Center - Valencia - Valencia
Alabama
- Advanced Cardiovascular, LLC - Alexander City Office - Alexander City
- Central Research Associates, Inc - Birmingham
- Cardiology, P.C. - Birmingham
- Synexus (Radiant Research, Inc) - Alabama - Simon Williamson Clinic Location - Birmingham
- G & L Research LLC - Foley - Foley
- Accel Research Sites (ARS) - Birmingham Clinical Research Unit - Vestavia Hills
Connecticut
- CMR of Greater New Haven - Hamden
- Chase Medical Research, LLC - Hamden - Waterbury
Arizona
- Del Sol Research - Tucson
Florida
- Indago Research and Health Center - Hialeah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,083 participants |
| Start Date | 2023-11-22 |
| Est. Completion | 2025-01-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06153693
The ClinicalTrials.gov registry entry for NCT06153693 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,083 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (69% lower). The listed sponsor is Mineralys Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06153693 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06153693 about?
NCT06153693 is a clinical study titled "Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension". This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.
What is the current status of trial NCT06153693?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,083 participants. The study started on 2023-11-22. Estimated completion is 2025-01-24.
What conditions does trial NCT06153693 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT06153693?
The interventions under investigation include: Placebo (DRUG), lorundrostat Dose 1 (DRUG), lorundrostat Dose 2 (DRUG).
Who is sponsoring clinical trial NCT06153693?
This trial is sponsored by Mineralys Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06153693 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.